跳至主要内容
临床试验/CTRI/2025/01/079296
CTRI/2025/01/079296尚未招募不适用

The objective of this study is to evaluate the non-comedogenic effect of skin care formulation, skin lightening face serum, on healthy human female subjects.

Sun Pharmaceutical Industries Ltd.1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2025年1月28日

试验速览

阶段
不适用
状态
尚未招募
入组人数
36
试验地点
1
主要终点
Non-comedogenic effect

研究概览

简要总结

OBJECTIVE: The objective of this study is toevaluate the non-comedogenic effect of skin care formulation, skin lightening face serum, on healthy human female subjects. The evaluation is performed using:Dermatologist Evaluation Efficacy: (Counting of total lesions ), Sebumetry, Subject Self Evaluation (SSE) Questionnaire (Comedogenic Effect& Safety), Subject Self Evaluation (SSE) Questionnaire (Cosmetic Appeal), Dermatological Evaluation: Safety

 POPULATION: 36 female subjects are selected for the study*.**-*Enrollment: 36 female subjects

*-*Completed: 30 female subjects

*The subjects selected for this study are healthy females, aged between 18 and 35 years,*presenting with oily or mixed oily skin on the face and presenting with mild to moderate acne.

 STUDY DURATION: Duration: 28 days following the first application of the product.

研究设计

研究类型
Interventional
分配方式
Na
盲法
Participant Blinded

入排标准

年龄范围
18.00 Year(s) 至 35.00 Year(s)(—)
性别
Female

入选标准

  • Indian female subjects 2Healthy subjects 3)Skin is healthy on the studied anatomic unit 4)Having oily or mixed oily skin type on the face.

排除标准

  • 1 Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2 Having refused to give her assent by not signing the consent form 3 Taking part in another study liable to interfere with this study 4 Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months) 5 Having a progressive asthma (either under treatment or last fit in the last 2 years) 6 Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area (except for specific studies on a determined dermatosis) 7 Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months) 8 Being epileptic.
  • 9 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 10 Having cutaneous hypersensitivity.
  • 11 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products.
  • 12 Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months.
  • 13 Having changed her cosmetic habits except those required by the protocol in the 14 days preceding the start of the study on the studied anatomic unit.

结局指标

主要结局

Non-comedogenic effect

时间窗: Baseline, Day 14, Day 28

次要结局

未报告次要终点

研究者

申办方类型
Pharmaceutical industry-Global
责任方
Principal Investigator
主要研究者

Dr Pooja Yadav

MASCOT-SPINCONTROL India Pvt. Ltd.

研究点 (1)

Loading locations...

相似试验